Abbisko Cayman Limited ( (HK:2256) ) has issued an update.
Abbisko Therapeutics announced the presentation of four late-breaking pre-clinical research results at the 2025 American Association for Cancer Research conference. The studies focused on ABSK112, ABSK131, and ABK-KRAS-1 inhibitors, highlighting their potential in treating cancer and addressing resistance mechanisms. These findings could significantly impact Abbisko’s market positioning by advancing their therapeutic pipeline and offering new treatment strategies for cancer patients.
More about Abbisko Cayman Limited
Abbisko Cayman Limited, through its subsidiary Abbisko Therapeutics, operates in the biotechnology industry focusing on the development of innovative cancer therapies. The company specializes in creating inhibitors targeting specific genetic mutations and pathways associated with cancer, aiming to provide effective treatment options for patients with various types of tumors.
YTD Price Performance: 65.00%
Average Trading Volume: 6,261,487
Technical Sentiment Signal: Sell
Current Market Cap: HK$5.16B
See more insights into 2256 stock on TipRanks’ Stock Analysis page.